Ryvu Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Ryvu Therapeutics has a total shareholder equity of PLN143.9M and total debt of PLN108.6M, which brings its debt-to-equity ratio to 75.5%. Its total assets and total liabilities are PLN378.8M and PLN234.9M respectively.
Key information
75.5%
Debt to equity ratio
zł108.64m
Debt
| Interest coverage ratio | n/a |
| Cash | zł225.93m |
| Equity | zł143.88m |
| Total liabilities | zł234.89m |
| Total assets | zł378.78m |
Recent financial health updates
Does Ryvu Therapeutics (WSE:RVU) Have A Healthy Balance Sheet?
Jan 15
Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Recent updates
Is Ryvu Therapeutics S.A. (WSE:RVU) Trading At A 30% Discount?
Feb 26Slammed 25% Ryvu Therapeutics S.A. (WSE:RVU) Screens Well Here But There Might Be A Catch
Jan 22Does Ryvu Therapeutics (WSE:RVU) Have A Healthy Balance Sheet?
Jan 15The Market Lifts Ryvu Therapeutics S.A. (WSE:RVU) Shares 26% But It Can Do More
Dec 07Despite Lacking Profits Ryvu Therapeutics (WSE:RVU) Seems To Be On Top Of Its Debt
Oct 20We're Keeping An Eye On Ryvu Therapeutics' (WSE:RVU) Cash Burn Rate
Aug 02Are Investors Undervaluing Ryvu Therapeutics S.A. (WSE:RVU) By 20%?
Jan 25What Type Of Shareholders Own The Most Number of Ryvu Therapeutics S.A. (WSE:RVU) Shares?
Feb 05Shareholders Of Ryvu Therapeutics (WSE:RVU) Must Be Happy With Their 261% Total Return
Dec 14Financial Position Analysis
Short Term Liabilities: RVU's short term assets (PLN272.4M) exceed its short term liabilities (PLN107.9M).
Long Term Liabilities: RVU's short term assets (PLN272.4M) exceed its long term liabilities (PLN127.0M).
Debt to Equity History and Analysis
Debt Level: RVU has more cash than its total debt.
Reducing Debt: RVU's debt to equity ratio has increased from 2.6% to 75.5% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: RVU has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: RVU has sufficient cash runway for 1.6 years if free cash flow continues to reduce at historical rates of 10.5% each year.
Discover healthy companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/24 04:35 |
| End of Day Share Price | 2025/03/21 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Ryvu Therapeutics S.A. is covered by 8 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mateusz Krupa | Biuro maklerskie mBanku |
| Jonas Peciulis | Edison Investment Research |
| Vladimira Urbankova | Erste Group Bank AG |